Latest
news
LR Health & Beauty SE publishes Q4 2025 report and advances financial and strategic initiatives
LR Health & Beauty SE publishes Q4 2025 report and advances financial and strategic initiatives
- FY 2025 sales reached EUR 277.1 million on a preliminary basis, with EBITDA reported of EUR 16.5 million
- Focus on implementing a new financing structure and initiating targeted strategic measures for long-term business development and growth
- Planned launch of new generation of products combining health and beauty expertise demonstrates innovative strength and sets important impulses for 2026
Ahlen, 24 February 2026 – LR Health & Beauty SE, Europe’s leading digital social commerce company for high-quality nutritional supplements and beauty products, today publishes its results for the fourth quarter of 2025 as well as preliminary sales and earnings results for the 2025 financial year.
The LR Group continued to face generally subdued consumer sentiment in Western European markets in the fourth quarter of 2025. LR Health & Beauty SE achieved sales (revenue from goods sold) of EUR 68.2 million in the fourth quarter 2025 (Q4 2024: EUR 76.5 million), representing a decrease of 10.9%. Accordingly, over the course of the full 2025 year, LR Health & Beauty SE posted a 4.6% year-on-year lower level of sales of EUR 277.1 million on a preliminary basis (2024: EUR 289.2 million).
Furthermore, LR Health & Beauty SE achieved EBITDA reported of EUR 0.3 million in the fourth quarter of 2025 (Q4 2024: EUR 8.3 million). The results in the final quarter were particularly affected by the lower sales level and exceptional items as part of the realignment of the financing structure. For the full 2025 year, reported EBITDA on a preliminary basis amounted to EUR 16.5 million compared with EUR 27.3 million in 2024. Normalized EBITDA in the fourth quarter of 2025 decreased to EUR 3.4 million, compared with EUR 9.5 million in the fourth quarter of the previous year. Accordingly, over the full course of 2025, normalized EBITDA amounted to EUR 22.5 million on the basis of preliminary figures (2024: EUR 32.6 million).
Jörg Körfer, CEO of LR Health & Beauty SE, comments: “In both financial and strategic terms, we are focusing consistently on creating the preconditions for sustainably positive business growth. We have recently reached an important milestone with the agreement concerning a realignment of the financing structure. At the same time, it is important in 2026 to advance the LR Group’s business with suitable strategic initiatives. One focus in this context is the further development of our product portfolio. In the spring, we are planning the promising launch of a new generation of products that combines expertise from the health and beauty areas and will provide our distribution partners with fresh impetus for their business activities.”
In developing high-quality dietary supplements and cosmetic products, LR regularly draws on the latest findings from science and research. Sustainability aspects are also given special consideration when optimising the product portfolio – including in the upcoming product launch.
The report for the fourth quarter of 2025 is available online from today on the company’s website at https://ir.lrworld.com/. The final, audited results for the 2025 financial year will be published at the end of April 2026 with the Annual Report on the company’s website.
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
Contact:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND SIGNIFICANTLY REDUCED DEBT STRUCTURE
Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND SIGNIFICANTLY REDUCED DEBT STRUCTURE
Ahlen, 11 February 2026 – Today, LR Health & Beauty SE (the “Company”) reached an agreement with bondholders representing more than two thirds (2/3) of the nominal amount of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) as well as the Company’s shareholder regarding a comprehensive restructuring of the Bonds and the Company’s capital structure.
The restructuring comprises an aggregate equity and debt injection of EUR 20 million in new capital, consisting of a (i) EUR 10 million equity contribution and (ii) EUR 10 million in New Money Senior Bonds (as defined below). The shareholder Evoco will continue its commitment to the Company demonstrating confidence and support to the Company.
The Company’s debt structure will be significantly downsized and restructured as follows:
- Senior secured debt of EUR 62.5 million comprising of the following tranches which will rank pari passu with each other and carry a fixed cash interest of 6.75% per annum:
- EUR 10 million new money senior bonds (the “New Money Senior Bonds”), to be subscribed for in cash by bondholders (offered pro rata to all bondholders). The New Money Senior Bond issue will be fully backstopped by certain major bondholders.
- EUR 20 million reinstated elevated bonds (the “Reinstated Elevated Bonds”), allocated pro rata to bondholders who participate in the New Money Senior Bonds.
- EUR 32.5 million reinstated bonds (the “Reinstated Bonds”), allocated pro rata to all existing bondholders.
- Unsecured subordinated junior bonds of EUR 27.5 million (the “Junior Bonds”), allocated pro rata to all existing bondholders, with payment-in-kind interest stepping up linearly from 6% per annum year one to 10% per annum year five, maturing in 2031.
- The part of the nominal amount of the Bonds (including accrued interest thereunder) that is not reinstated into Reinstated Elevated Bonds, Reinstated Bonds or Junior Bonds shall be written off in its entirety.
The agreement is set out in a lock-up agreement entered into between the Company, its shareholder and bondholders representing more than two thirds (2/3) of the nominal amount for the Bonds, whereunder inter alia the parties have undertaken to implement the comprehensive restructuring and the bondholders have agreed to not accelerate the Bonds during the lock-up period (ending 30 April 2026). Implementation of the restructuring is subject to approval by bondholders in one or several written procedures and by formal shareholder approval, and shall be completed by the end of the lock-up period.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
End of inside information
LR Health & Beauty SE lays foundation for positive future business performance with new financing structure
LR Health & Beauty SE lays foundation for positive future business performance with new financing structure
- Company receives EUR 20 million of new capital and significantly reduces debt
- Sustainable financing structure creates basis to implement targeted strategic measures to consistently drive LR’s success story
Ahlen, 11 February 2026 – LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has today taken an important step to realign its financing structure. An agreement was reached with significant investors in the Company concerning a comprehensive restructuring of its 2024/2028 Bond (ISIN: NO0013149658) (the “Bond”) and the Company’s capital structure. This agreement provides for an aggregate injection of fresh capital of EUR 20 million. At the same time, the Company's debt structure is being significantly reduced and restructured.
Jörg Körfer, Chief Executive Officer of LR Health & Beauty SE, comments: “With this agreement on a realignment of our financing structure, we have reached an important milestone to reposition the LR Group to make it viable for the future. On the basis of a solid financing structure, we aim to initiate targeted strategic measures to now bring the LR Group onto a successful trajectory. The consistent digitalisation of our business processes, a focused further development of our product portfolio and our expansion into new markets are to play a central role in this context. Furthermore, our strong partner community represents an important foundation for the future success of our Company. Following the successful start-of-year events and the launch of an innovative new product under the LR Body Mission brand, we aim to create additional incentives for our partners' activities in the course of the year with promising product innovations.”
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
Contact:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
"With innovative product solutions that cater to people’s growing health consciousness, we are fully on-trend."